BioStock: Follicum finalises patient recruitment in hair growth study

Alopecia patients have very few treatment options available to them. Those that exist are often ineffective and come with a multitude of side effects, and they mainly target men. Follicum’s FOL-005 is a compound in clinical development that has the potential not only to compete against current hair-loss medications in terms of efficacy, but it could potentially treat women as well as it could men. The Swedish biotech company recently announced it has completed patient recruitment for its phase II study and look forward to presenting data in the first half of 2021.

Read the full article at biostock.se:

https://www.biostock.se/en/follicum-finalises-patient-recruitment-in-hair-growth-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se